Biotech Values

[DewDiligence]

Notes on HIV market size and share
(from GILD CC):


US patients (all lines)
175K on Truvada-based regimens (32% share)
146K on Atripla (27% share)
043K on other Viread regimens (8% share)
===
364K on Viread in some form (68% share)

175K on non-Viread regimens (32% share)
===
539K total patients, +8% year-over-year

Atripla/Truvada has 80% share in first-line setting
(#msg-26915314)


Top-5 EU countries (all lines)
259K total patients, +7% year-over-year

Atripla/Truvada has 68% share in first-line setting


p.s. Hepsera market share in HBV: 43% US, 36% ex-US



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”